dactinomycin has been researched along with isoniazid in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (35.71) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Devi, PB; Nallangi, R; Samala, G; Sriram, D; Yogeeswari, P | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blake, RL; Blake, SL; Kun, E; Loh, HH | 1 |
| Le, NT; Richardson, DR | 1 |
| Liang, SX; Richardson, DR | 1 |
| SAMPEY, JR | 1 |
| Lui, A; Znidarić, D | 3 |
2 review(s) available for dactinomycin and isoniazid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
NEW AND OLD DRUGS IN THE MANAGEMENT OF HODGKIN'S DISEASE.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Anti-Bacterial Agents; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Dexamethasone; Folic Acid Antagonists; Hodgkin Disease; Humans; Isoniazid; Mannomustine; Melphalan; Methotrexate; Mitomycin; Mitomycins; Nitrogen Mustard Compounds; Phenylbutazone; Prednisolone; Prednisone; Thiotepa | 1964 |
12 other study(ies) available for dactinomycin and isoniazid
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors.
Topics: Animals; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Mice; Molecular Structure; Mycobacterium tuberculosis; Peptide Synthases; Pyrazoles; Pyridines; Structure-Activity Relationship | 2013 |
The effect of nicotinamide and homologs on the activity of inducible enzymes and NAD content of the rat liver.
Topics: Animals; Brain; Dactinomycin; Enzyme Induction; Hydrocortisone; Hypophysectomy; Isoniazid; Kidney; Liver; Male; Muscles; Myocardium; NAD; Niacinamide; Nicotinic Acids; Nikethamide; Pyridines; Rats; Tryptophan Oxygenase; Tyrosine Transaminase | 1967 |
Potent iron chelators increase the mRNA levels of the universal cyclin-dependent kinase inhibitor p21(CIP1/WAF1), but paradoxically inhibit its translation: a potential mechanism of cell cycle dysregulation.
Topics: Cell Cycle; Cells, Cultured; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Dactinomycin; Deferoxamine; DNA Damage; Gene Expression Regulation; Humans; Iron Chelating Agents; Isoniazid; Multienzyme Complexes; Proteasome Endopeptidase Complex; Protein Biosynthesis; Receptors, Transferrin; RNA, Messenger; Tumor Suppressor Protein p53 | 2003 |
The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
Topics: Blotting, Northern; Blotting, Western; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dactinomycin; Electrophoretic Mobility Shift Assay; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Genes, Reporter; Humans; Iron Chelating Agents; Isoniazid; Protein Synthesis Inhibitors; RNA, Messenger; Transcription, Genetic; Transcriptional Activation; Transfection; Tumor Suppressor Protein p53 | 2003 |
Regeneration of proximal and distal part of hydra body cut in the middle of gastral cavity and treated with dactinomycine.
Topics: Animals; Dactinomycin; Hydra; Regeneration | 1977 |
Effects of dactinomycine (actinomycine D) on budless hydra and during its budding process.
Topics: Animals; Dactinomycin; Hydra | 1976 |
Effects of ultraviolet light (2535 A) and dactinomycin upon hydra (Pelmatohydra oligactis).
Topics: Animals; Dactinomycin; Hydra; Time Factors; Ultraviolet Rays | 1981 |